Loading...Loading...Monday, Mirum Pharmaceuticals Inc. MIRM announced interim results from two Phase 2b studies evaluating volixibat for primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC).Interim results from the VANTAGE study evaluating volixibat in patients with PBC demonstrated a statistically significant (-3.82, p<0.0001) improvement in pruritus (itch) for volixibat and a placebo-adjusted difference of -2.32 points in the primary endpoint, p=0.0026, as measured by the Adult ItchR ...